Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Gilead Sciences has received FDA approval for the hepatitis C virus (HCV) treatment Harvoni, a single pill that combines the already-approved antiviral sofosbuvir—marketed as Sovaldi—and a new antiviral, ledipasvir. Approved in December, Sovaldi gained notoriety as the most successful drug launch in history, racking up $5.8 billion in sales in the first half of this year. It has also come under scrutiny for its cost: $1,000 per pill. Harvoni will be $1,125 per tablet, putting a $94,500 price tag on a typical 12-week regimen of the drug. Gilead’s potential windfall from Harvoni could be stunted by state Medicaid plans, many of which are already putting limits on who can have Sovaldi.
This article has been sent to the following recipient: